Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHRONULAC vs SOMA COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy)
Relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: management of muscle spasms, tension headaches
10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.
1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Carisoprodol: approximately 2-4 hours in adults with normal renal function. Meprobamate: approximately 10-12 hours. The prolonged half-life of meprobamate contributes to accumulation with repeated dosing, especially in elderly or renally impaired patients, leading to increased risk of sedation and dependence.
Not absorbed systemically; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite); aspirin is hydrolyzed to salicylic acid via esterases in the liver and plasma.
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Carisoprodol and its active metabolite meprobamate are primarily excreted renally. Approximately 60% of a dose is eliminated as unchanged carisoprodol and meprobamate in urine, with the remainder as various hydroxylated metabolites. Less than 1% is eliminated in feces. Meprobamate undergoes hepatic metabolism, and about 10-20% is excreted unchanged in urine.
Negligible (<5%), primarily to albumin.
Carisoprodol: approximately 60% bound to plasma proteins, primarily albumin. Meprobamate: approximately 15-25% bound to plasma proteins.
Approximately 0.25 L/kg; distributes mainly into extracellular fluid.
Carisoprodol: Vd approximately 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding. Meprobamate: Vd about 0.7 L/kg.
Oral: poorly absorbed; <3% reaches systemic circulation as intact lactulose; the remainder is metabolized by colonic bacteria.
Oral: Carisoprodol is well absorbed with bioavailability >90%. The absorption rate may be slightly reduced with food, but extent is not significantly affected.
No dose adjustment required for renal impairment; caution in severe renal impairment due to electrolyte disturbances.
Cr Cl <30 m L/min: avoid use due to aspirin component; Cr Cl 30-50 m L/min: reduce dose or extend interval; monitor for carisoprodol accumulation.
No adjustment needed; used in hepatic encephalopathy at higher doses.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Infants: 2.5-5 m L orally once daily; Children 1-5 years: 5-10 m L once daily; Children 6-12 years: 10-15 m L once daily; Adolescents: 15-30 m L once daily; adjust based on response.
Not recommended for children under 12 years; safety and efficacy not established.
Start at low end of dosing range (10-15 m L once daily) due to increased risk of electrolyte imbalance and dehydration; monitor fluid/electrolyte status.
Initiate at lowest dose (1 tablet); avoid use in patients with Cr Cl <30 m L/min; monitor for CNS depression and bleeding risk.
None.
No FDA black box warning.
Electrolyte disturbances (e.g., hypernatremia, hypokalemia) with prolonged use or high doses,Diarrhea may cause fluid and electrolyte loss,Risk of colonic distention or fecal impaction,Use caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (contains galactose and lactose)
Dependence and withdrawal: Carisoprodol can cause dependence, abuse, and withdrawal symptoms after prolonged use,Sedation: May impair mental or physical abilities; caution with driving or operating machinery,Bleeding risk: Aspirin component increases risk of bleeding, especially with alcohol, anticoagulants, or existing bleeding disorders,Hypersensitivity: Allergic reactions including anaphylaxis can occur
Patients with galactosemia,Intestinal obstruction,Known hypersensitivity to lactulose
History of acute intermittent porphyria,Hypersensitivity to carisoprodol, meprobamate, aspirin, or any component,Severe hepatic or renal impairment,Gastrointestinal bleeding or peptic ulcer disease (active),Children with viral infections (Reye's syndrome risk),Third trimester of pregnancy (aspirin component)
No specific food interactions, but avoid concurrent use with other laxatives. Ensure adequate fluid intake to reduce risk of hypernatremia.
Avoid alcohol. Aspirin may cause gastrointestinal irritation; take with food or a full glass of water to reduce risk. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not conducted. Based on lack of systemic absorption, risk to fetus is low across all trimesters.
Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin component (if present in compound) is associated with increased risk of neural tube defects and fetal hemorrhage if used in third trimester. Avoid use during pregnancy unless benefit outweighs risk.
Lactulose is not absorbed orally; therefore, excretion into breast milk is negligible. Considered compatible with breastfeeding; no M/P ratio available due to lack of systemic absorption.
Carisoprodol and its active metabolite meprobamate are excreted in breast milk. M/P ratio not well established. Concentrations may reach clinical significance. Potential for infant sedation, hypotonia, or withdrawal. Avoid breastfeeding while on this medication.
No dose adjustment required during pregnancy. Pharmacokinetics of lactulose are unchanged due to lack of systemic absorption. Use standard dosing for constipation (15-30 m L daily, titrated to effect).
No established dosing adjustments for pregnancy. Due to increased renal clearance during pregnancy, consider that standard doses may be less effective. However, lack of safety data generally contraindicates use. If absolutely necessary, use lowest effective dose for shortest duration.
Chronulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Onset of action for constipation is 24-48 hours; monitor for electrolyte disturbances (hypernatremia) with prolonged use. Do not use with other laxatives in acute abdomen. For hepatic encephalopathy, titrate to 2-3 soft stools daily.
Soma Compound contains carisoprodol (a centrally acting muscle relaxant) and aspirin (an NSAID). Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with a history of substance abuse, porphyria, or G6PD deficiency. Monitor for signs of CNS depression, especially when combined with alcohol or other sedatives. Aspirin increases bleeding risk; avoid in patients with bleeding disorders or those on anticoagulants. Do not use in children or adolescents with viral infections due to risk of Reye's syndrome.
May take 24-48 hours to produce a bowel movement; do not use if you have abdominal pain, nausea, or vomiting.,Mix with fruit juice, milk, or water to improve taste.,Store at room temperature; do not freeze.,Report excessive diarrhea or electrolyte imbalance symptoms (muscle cramps, weakness).
Take exactly as prescribed; do not increase dose or frequency.,Do not drive or operate heavy machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report any signs of bleeding (bruising, black stools, blood in urine) or allergic reactions (rash, swelling, difficulty breathing).,Do not use in children or teenagers with chickenpox or flu symptoms due to risk of Reye's syndrome.,This medication may be habit-forming; do not stop abruptly without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHRONULAC vs SOMA COMPOUND, answered by our medical review team.
CHRONULAC is a Osmotic Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.. SOMA COMPOUND is a Skeletal Muscle Relaxant Combination that works by Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHRONULAC and SOMA COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHRONULAC is: 10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.. The standard adult dose of SOMA COMPOUND is: 1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHRONULAC and SOMA COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHRONULAC is classified as Category C. Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not . SOMA COMPOUND is classified as Category C. Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin com. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.